Opinion|Videos|August 8, 2024
Interpreting and Communicating ctDNA Results
The panel examines challenges in interpreting circulating tumor DNA results and their impact on clinical decision-making processes.
Advertisement
Episodes in this series
- How do you factor ctDNA into treatment selection and management?
- How do you integrate ctDNA with radiographic or pathologic correlates?
- Are there challenges associated with the interpretation of ctDNA to inform your clinical decision-making?
- What do we know about sensitivity of ctDNA with different sites of metastatic disease?
- Navigating positive results
- Navigating false negatives
- How do you describe these test results to patients?
- Do you have any practical insights to share for interpretating and presenting results?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
The FDA cleared the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures such as colorectal cancer screening and lesion removal.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
The FDA has set a new action date of March 3, 2027, for zanzalintinib/atezolizumab for previously treated metastatic colorectal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
3
Cevostamab Combo Shows Durable Responses in R/R Multiple Myeloma
4
FDA Clears TriNav Advance for Expanded Liver Embolization Access
5